Dan Spencer’s Post

Did you know that the FDA has approved 11 bispecific antibodies (bsAbs) to treat cancer?[1] Whether it's trispecifics, bsAb prodrugs, bsAbs that induce degradation of tumor targets. or bsAbs acting as cytokine mimetics, Certis Oncology partners with preclinical drug developers to understand MOA and test the efficacy of next-generation, early-stage bsAbs for the treatment of solid tumors. Contact us today to learn more: https://hubs.la/Q02Jqy0f0. #CancerResearch #Bispecifics #Antibodies #FightCancer [1]Klein C et al. The Present and Future of Bispecific Antibodies for Cancer Therapy. Nat Rev Drug Discov 23, 301–319 (2024).

Advancements in the Genitourinary Cancer Market! ASCO 2024 conference is poised to unveil groundbreaking advancements in the realm of genitourinary cancers, focusing on prostate cancer, bladder/urothelial cancer, and renal cell carcinoma. Leading pharmaceutical giants like Novartis, Pfizer, Merck, Arvinas, Astellas Pharma, Janssen Inc., Orion Pharma Ltd, and others are gearing up to present their latest research and developments, sparking significant interest and discussions throughout the event. A major highlight of ASCO 2024 will be CG Oncology's final results from the CORE-001 Phase II trial of cretostimogene in combination with KEYTRUDA. These findings are anticipated to signal a potential paradigm shift in the treatment landscape for NMIBC, offering newfound hope for patients unresponsive to traditional BCG therapy. To get exclusive insights on the genitourinary cancer treatment market, visit: https://lnkd.in/gnwgiqqt #ASCO2024 #GenitourinaryCancers #ProstateCancer #BladderCancer #RenalCellCarcinoma #PharmaResearch #Novartis #Pfizer #Merck #Arvinas #AstellasPharma #Janssen #OrionPharma #MedicalInnovations #CancerTreatment #ClinicalTrials #NMIBC #BCGTherapy #CancerResearch #HopeForPatients

🚀 Exciting Announcement from Axella Research! 🚀 We are thrilled to share that Mirror Biologics is starting up a new Phase 2 clinical trial in collaboration with Axella Research, focusing on advanced metastatic colorectal cancer (CRC). This trial, titled "COMUNITY" (NCT06557278), combines AlloStim® with an anti-PD-L1 therapy to potentially convert "cold" tumors into "hot" ones, making them responsive to immunotherapy. Key Details: -Target: Chemotherapy and immunotherapy-refractory MSS metastatic CRC patients. -Treatment: AlloStim® in combination with Bavencio (Avelumab). -Objective: To assess safety and efficacy as a fourth-line treatment. Estimated Enrollment: 50 participants. We invite investigators and clinical research sites interested in participating in this groundbreaking study to reach out to us for collaboration opportunities. email: trials@axellaresearch.com Stay tuned for updates as we advance in this critical research! #ClinicalResearch #Oncology #Immunotherapy #AxellaResearch #MirrorBiologics #ClinicalTrials #CancerTreatment

Ovarian cancer remains one of the deadliest cancers affecting women, often going undetected until it has reached an advanced stage, resulting in a poor five-year survival rate of only 50.9%.    https://lnkd.in/djGhVz9J    The pressing need to reduce ovarian cancer mortality emphasizes the importance of raising awareness and advancing oncology research. A promising new treatment developed by Nuvectis Pharma, Inc., NXP800, has just been granted FDA Orphan Drug Designation. This small molecule inhibitor targeting ARID1a-mutated ovarian cancer, is currently in a Phase 1b clinical trial evaluation, offering hope to ovarian cancer patients.    https://lnkd.in/eJ6iia7f   #OvarianCancerAwareness 

#Melanoma_Cancer_Diagnostics Market Share Expected Huge Growth during 2022-2030 https://lnkd.in/dE8CtT8X The market for #melanoma cancer diagnostics is predicted to grow as the prevalence of melanoma skin #cancer rises. Increased exposure to ultraviolet radiation in factories, the sun, and other places eventually leads to increased melanoma skin cancer instances, propelling the melanoma cancer #diagnostic market forward. Inhalation Sciences Sweden AB Incyte Merck Group Novartis Pierre Fabre Group Amgen Amgen Deutschland AstraZeneca Bristol Myers Squibb Bristol Myers Squibb UK & Ireland Daiichi Sankyo, Inc.

At ESMO - European Society for Medical Oncology 2024, HER2-targeting antibody-drug conjugates (ADCs) generate significant attention as potential breakthroughs for HER2-positive cancers, particularly breast, gastric, and urothelial cancers. KADCYLA (trastuzumab emtansine), developed by Genentech/Roche and approved in 2013, has been a leading HER2-targeting ADC for breast cancer, serving as a standard treatment for over a decade. However, ENHERTU (trastuzumab deruxtecan), developed by Daiichi Sankyo US and AstraZeneca, is emerging as a stronger competitor. ENHERTU, approved for both HER2-positive and HER2-low breast cancer, offers enhanced efficacy with a higher drug-to-antibody ratio and a more potent payload, leading to improved progression-free survival (PFS) and overall survival (OS) compared to KADCYLA. As KADCYLA nears patent expiration, ENHERTU is poised to become the preferred treatment for all HER2-expressing cancers, potentially replacing conventional chemotherapy. Unlock the Power of Expert Insights and Thorough Analysis with DelveInsight Business Research LLP's ESMO 2024 Exclusive Coverage @ https://lnkd.in/dz2u_DWG #esmo #esmo2024 #esmoconference #conference #esmocoverage #detailedinsights #pharma #pharmaceutical

James Nathanielsz, CEO of Propanc Biopharma, Inc. (OTCQB:PPCB) is Featured in an Interview With SmallCapsDaily   Propanc CEO, James Nathanielsz Discusses the Company's Groundbreaking Therapy, PRP, and its Potential to Revolutionize Cancer Treatment   Propanc Biopharma, Inc. (QB - PPCB), is pleased to announce its CEO, James Nathanielsz, recently conducted an interview with SmallCapsDaily discussing the Company's recent developments, including the initiation of a Phase Ib study for their innovative pancreatic proenzyme therapy, PRP, highlighting its potential to transform cancer treatment. Nathanielsz shared insights into the company's goals, intellectual property strategy, and the positive patient outcomes observed during compassionate patient treatment, underscoring Propanc's commitment to advancing impactful solutions in the field of oncology.   To read the full interview visit: https://lnkd.in/gcHCx7Q2   https://lnkd.in/gSwXQeKw   #propanc #ppcb #biopharma #cancer #oncology

Zion Pharma's ZN-A-1041 is being considered for breakthrough therapy designation by the CDE of the NMPA. This promising drug is intended for use in combination with capecitabine and trastuzumab for treating HER2-positive patients with advanced breast cancer who have brain metastases and have experienced disease progression despite previous trastuzumab-based treatments. Developed by Zion Pharma, ZN-A-1041 is a potential best-in-class oral HER2 inhibitor with exceptional blood-brain barrier penetration. This characteristic makes it a promising solution for both treating and preventing brain metastases in HER2-positive breast cancer patients. Given that up to 50% of HER2-positive metastatic breast cancer patients may develop brain metastases, this advancement is highly significant. In May 2023, Roche secured global rights for the development, manufacturing, and commercialization of ZN-A-1041 through its partnership with Zion Pharma. #BreastCancer #HER2Inhibitors #CancerTreatment #PharmaInnovation #DrugDevelopment #Roche #BreakthroughTherapy #Oncology #MedicalResearch #QimingPortfolio #QimingHealthcare

We are pleased to share the results from our preclinical studies demonstrating that our drug #bisantrene, when used in combination with another cancer drug #decitabine, offers significantly improved cancer cell-killing across a broad panel of 143 tumour cell lines. Notably, the combination of these drugs is much more effective than either compound taken on its own. CEO Dr Daniel Tillett comments: “These results open exciting new treatment opportunities for both bisantrene and decitabine. While decitabine has proven its effectiveness in haematological cancers, it has not demonstrated clinical utility in solid tumours, like lung or breast cancer. This new body of work is highly supportive of the results from the University of Newcastle in preclinical AML models using a combination of bisantrene and decitabine. Thanks to the continued support of our shareholders, we are looking forward to announcing a clinical trial of this promising anticancer drug combination in the near future.”   More details here: https://lnkd.in/gsEKzZK6 #CancerTreatment #KillCancer

Today on World Lung Cancer Day, we want to raise awareness of the most aggressive form of lung cancer: Small Cell Lung Cancer (#SCLC). At DISCO Pharmaceuticals GmbH, using our target discovery platform, we have completed the first-ever mapping of the SCLC #surfaceome. This has revealed countless novel proteins and protein communities on the surface of SCLC cells providing target🎯candidates for mono- and bi-specific #antibodytherapeutics Using this knowledge, we have launched the development of SCLC target-specific therapeutics to improve #patient care by providing more effective, targeted treatment options. To learn more about our cell surfaceome discovery technology, visit the link in the comments below. #WorldLungCancerDay #WLCD2024 #LungCancerAwareness #SmallCellLungCancer